Teva Pharmaceutical Industries Limited

TEVA

Drug Manufacturers - Specialty & Generic · Healthcare

Exchange

New York Stock Exchange

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Strong

Stability

Mixed

Valuation

Good

Track this stock — start free trial

Winston Score History

The full picture

Teva Pharmaceutical Industries makes medicines and sells them to patients, hospitals, and pharmacies around the world. The company is best known for generic drugs — cheaper copies of brand-name medicines that work the same way — and it is one of the largest generic drug makers on the planet. Teva also makes a small number of its own branded medicines, including Austedo for movement disorders and Ajovy for migraines.

Teva earns money by selling both generic and branded drugs, with generics making up the majority of its revenue. The company operates globally, with strong businesses in the United States, Europe, and Israel, and it generates roughly $16 billion in annual revenue. Teva carries a heavy debt load from a costly acquisition spree in the 2010s, and it has spent years working to pay that debt down while also settling billions of dollars in opioid-related lawsuits in the U.S. The key question going forward is whether growth from newer branded drugs can offset ongoing price pressure in the highly competitive generics market.

Politician Trades

1 trades / 12mo

1 Congressional buy and 0 sells on TEVA in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-0.8% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-296.0% YoY

YoY Growth Rate

Earnings declining

Insider Activity

0.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$3.7B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Teva Pharmaceutical Industries Limited's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

52.0%

Healthy — 52.0% gross margin

Profit after running costs

Operating Margin

3.6%

Thin — 3.6% operating margin

Return on the money invested

ROCE

8.1%

Below par — 8.1% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+4.1%

Slow sales growth (+4.1% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

313%

Turns 313% of profit into real cash

Spare cash per sale

FCF Margin

9.6%

Modest free cash flow (9.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

2.18

Heavy debt load (2.18)

Covers its interest

Interest Cover

2.20x

Tight — interest eats into profit (2.2x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

57.7x

no trend

Expensive — P/E 57.7

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+47.6

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (57.7 → 10.2)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial